XML 31 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
FAIR VALUE MEASUREMENTS (Details Textual) (USD $)
12 Months Ended 13 Months Ended 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Dec. 29, 2011
Dec. 31, 2010
Manhattan and Ariston Pharmaceuticals Merger [Member]
Dec. 31, 2012
Manhattan and Ariston Pharmaceuticals Merger [Member]
Dec. 31, 2011
Manhattan and Ariston Pharmaceuticals Merger [Member]
Notes Issued         $ 15,452,793    
Debt Instrument Maturity Period         5 years    
Impairment of in-process research and development 1,104,700 0 1,104,700        
Debt Instrument, Interest Rate, Effective Percentage         5.00% 5.00% 5.00%
Debt Instrument, Convertible, Conversion Price         $ 1,125    
Percentage Of Cash Proceeds From Operation To Repay Convertible Debt         50.00%    
Long-term Debt, Gross 17,727,000 16,883,000 17,727,000 16,876,000      
Debt Instrument, Fair Value Disclosure 3,287,700   3,287,700        
Fair Value Inputs, Discount Rate 20.00% 20.00%          
Repayments Of Long-Term Debt $ 0